M. Eynatten

发表

Circulating Adipocyte Fatty Acid-Binding Protein Levels and Cardiovascular Morbidity and Mortality in Patients With Coronary Heart Disease: A 10-year Prospective Study

H. Brenner, D. Rothenbacher, L. Breitling, 2012, Arteriosclerosis, thrombosis, and vascular biology.

Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease

P. Lepper, B. Allolio, P. Nawroth, 2007, Diabetologia.

Fetuin-A and arterial stiffness in patients with normal kidney function

J. Staessen, U. Heemann, J. Lutz, 2009, Regulatory Peptides.

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double‐blind, placebo‐controlled study

H. Woerle, T. Haak, T. Meinicke, 2012, Diabetes, obesity & metabolism.

The Renal Hemodynamic Effect of SGLT 2 Inhibition in Patients with Type 1 Diabetes

U. Broedl, H. Woerle, B. Perkins, 2013 .

Adiponectin and prognostic outcome in patients with coronary artery disease: Reply

H. Brenner, D. Rothenbacher, M. Eynatten, 2008 .

pof Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction

V. Perkovic, P. Groop, M. Cooper, 2013 .

Original Investigation Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes

J. McGill, J. Rosenstock, C. Wanner, 2015 .

Levels of three distinct p75 neurotrophin receptor forms found in human plasma are altered in type 2 diabetic patients

A. Hamann, A. Bierhaus, P. Nawroth, 2007, Diabetologia.

Low pre-transplant adiponectin multimers are associated with adverse allograft outcomes in kidney transplant recipients a 3-year prospective study

F. Heinemann, U. Heemann, O. Witzke, 2012, Regulatory Peptides.

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

U. Broedl, H. Woerle, B. Perkins, 2014, Diabetologia.

The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes

P. Groop, M. Cooper, H. Woerle, 2016, Diabetologia.

Atorvastatin increases lipoprotein lipase expression in vitro and activity in vivo.

K. Dugi, M. Eynatten, J. G. Schneider, 2005, Journal of atherosclerosis and thrombosis.

Long‐term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes

R. Kawamori, H. Watada, E. Araki, 2013, Diabetes, obesity & metabolism.

SP259EFFECTS OF EMPAGLIFLOZIN ON RENAL OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL

A. Levin, C. Wanner, V. Perkovic, 2017 .

German Community Acquired Pneumonia Competence Network: Admission Serum Glucose Levels: A risk factor predicting mortality in community acquired pneumonia - data from the prospective CAPNETZ Cohort Study

C. Schumann, T. Welte, Mathias W Pletz, 2012 .

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

J. Rosenstock, H. Woerle, B. Gallwitz, 2012, The Lancet.

Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA1c < 7% with no hypoglycaemia and no weight gain over 2 years

J. Rosenstock, H. Woerle, B. Gallwitz, 2013, International journal of clinical practice.

Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18‐week randomized, double‐blind, placebo‐controlled phase III trial with a 34‐week active‐controlled extension

A. Barnett, S. Patel, H. Woerle, 2012, Diabetes, obesity & metabolism.

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial

H. Woerle, A. Barnett, Russell Jones, 2013, The Lancet.

Abstract 15997: Empagliflozin Exerts Short- and Long-term Effects on Plasma Volume in Patients With Type 2 Diabetes: Insight From EMPA-REG OUTCOME

B. Zinman, C. Wanner, D. Fitchett, 2017 .

Urinary adiponectin in type 2 diabetes Urinary Adiponectin Excretion : A Novel Marker for Vascular Damage in Type 2 Diabetes Running title : Urinary adiponectin in type 2 diabetes

K. Amann, B. Allolio, P. Nawroth, 2009 .

SO019EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL

A. Levin, C. Wanner, V. Perkovic, 2017 .

Urinary excretion of high molecular weight adiponectin is an independent predictor of decline of renal function in type 2 diabetes

C. Forsblom, P. Groop, M. Kieser, 2013, Acta Diabetologica.

SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME® TRIAL

B. Zinman, C. Wanner, P. Ruggenenti, 2018 .

Long-Term Efficacy and Safety of Linagliptin in PatientsWith Type 2 Diabetes and Severe Renal Impairment A 1-year, randomized, double-blind, placebo-controlled study

J. McGill, H. Woerle, M. von Eynatten, 2012 .

37-LB: Very-Low-Dose Premeal Whey Protein Microgels Reduce Postprandial (PP) Glucose in Type 2 Diabetes: A Randomized, Placebo-Controlled Crossover Study

E. Berk, B. Ahrén, O. Johansen, 2021, Diabetes.

Reduction of Postprandial Hyperglycemia in Patients with Type 2 Diabetes Reduces NF-κB Activation in PBMCs

B. Isermann, S. Schiekofer, A. Hamann, 2004 .

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

H. Woerle, M. Ackermans, M. Serlie, 2012, Cardiovascular Diabetology.

Urinary L‐FABP and anaemia: distinct roles of urinary markers in type 2 diabetes

P. Nawroth, A. Bierhaus, U. Heemann, 2010, European journal of clinical investigation.

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

J. Rosenstock, H. Woerle, B. Gallwitz, 2012, The Lancet.

Postprandial mononuclear NF-kappaB activation is independent of the AGE-content of a single meal.

J. Schneider, M. Andrassy, E. Schleicher, 2006, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18‐week randomized, double‐blind, placebo‐controlled phase III trial with a 34‐week active‐controlled extension

H. Woerle, S. Patel, S. Thiemann, 2012, Diabetes, obesity & metabolism.

Recurrent deep venous thrombosis caused by congenital interruption of the inferior vena cava and heterozygous factor V Leiden mutation

P. Nawroth, P. Nawroth, K. Dugi, 2002, Journal of internal medicine.